StockData
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Xeris Biopharma Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)

Close on Oct 19, 2026

Market cap
$1.89B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open$92.10M$-0.18–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026Before market open$83.13M$0.01–
Q4 FY2025
Ended Dec 31, 2025
Jan 8, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open$74.38M$0.00–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open$71.50M$-0.01–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open$60.12M$-0.06–
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025Before market open$60.10M$-0.03–
Q3 FY2024
Ended Sep 30, 2024
Nov 8, 2024Before market open$54.30M$-0.11$-0.06
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open$48.10M$-0.10–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Mar 6, 2024Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
total revenuefull-year 2026$385.00M to $390.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Xeris Biopharma filed with the SEC